Good morning. My name is Andrea, and I will be your conference operator today. At this time, I would like to welcome everyone to the Novanta Incorporated's 2023 fourth quarter and full-year earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. To ask a question, you may press star, then one on your touch-tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Ray Nash, Corporate Finance Leader for Novanta. Please go ahead. Thank you very much. Good morning and welcome to Novanta's fourth quarter and full-year 2023 earnings conference call. I am Ray Nash, Corporate Finance Leader for Novanta. With me on today's call is our Chair and Chief Executive Officer, Matthijs Glastra, and our Chief Financial Officer, Robert Buckley. If you have not received a copy of our earnings press release issued today, you may obtain it from the Investor Relations section of our website at www.novanta.com. Please note this call is being webcast live and will be archived on our website shortly after the call. Before we begin, we need to remind everyone of the safe harbor for forward-looking statements that we've outlined in our earnings press release issued earlier today and also those in our SEC filings. We may make some comments today, both in our prepared remarks and in our responses to questions that may include forward-looking statements. These involve inherent assumptions with known and unknown risks and other factors that could cause our future results to differ materially from our current expectations. Any forward-looking statements made today represent our views only as of this time. We disclaim any obligation to update forward-looking statements in the future, even if our estimates change. So you should not rely on any of these forward-looking statements as representing our views as of any time after this call. During this call, we will be referring to certain non-GAAP financial measures. A reconciliation of such non-GAAP financial measures to the most directly comparable GAAP measures is available as an attachment to our earnings press release. To the extent that we use non-GAAP financial measures during this call that are not reconciled to GAAP measures in the earnings press release, we will provide reconciliations promptly on the Investor Relations section of our website after this call. I'm now pleased to introduce the Chair and Chief Executive Officer of Novanta, Matthijs Glastra. Thank you, Ray. Good morning, everybody, and thanks for joining our call. Novanta delivered solid performance in 2023 in the fourth quarter and for the full year. I'm very proud of how our teams delivered revenue and profit performance above our expectations in a dynamic market environment. For the full year of 2023, we achieved record $882 million in revenue, expanded adjusted gross margins by over 100 basis points to 47%, and expanded adjusted EBITDA to $196 million, a 100 basis point improvement in EBITDA margins. Our sales grew 2% year-over-year on a reported basis and 1% on an organic basis. Excluding microelectronics applications, our growth for the full year was up high single digits. For the fourth quarter, we delivered $212 million in revenue, which represents a decline of 3% on a reported basis and a decline of 4% on an organic basis. Excluding microelectronics, our organic growth was down approximately 1%. Adjusted EBITDA was greater than $45 million, beating our expectations and prior guidance. Operating cash flow was very strong for the second straight quarter at approximately $39 million, which represents more than 300% conversion to net income. This operating performance reflects excellent execution by our teams in a challenging macroeconomic environment. In addition to all of this, in 2023, we signed an agreement to acquire Motion Solutions, which will enhance our portfolio and further expand our presence in the highly attractive medical and precision medicine space. We're happy to have completed the acquisition at the beginning of January 2024. The sticky Novanta business model with diversified exposure to long-life cycle customer platforms in secular high-growth markets has proven resilient under multiple geopolitical and macroeconomic scenarios. Our proprietary technologies are well-positioned in medical and advanced industrial applications with long-term secular tailwinds such as robotics and automation, minimally invasive and robotic surgery, and precision medicine. Medical applications made up 54% of our sales in 2023 versus a single-digit percentage of sales a decade ago, which we believe provides Novanta with greater resilience during fluctuating macroeconomic conditions. We feel that our strong customer relationships with the leading OEMs in these secular growth applications to strengthen diversification of our portfolio and our sticky business model allow Novanta to drive robust performance through the economic cycles. In the fourth quarter, the broader end-market themes were that medical markets continue to be strong, life sciences and advanced industrial markets slowed down in line with the PMI indices and interest rate environment, and microelectronics stabilized. Life sciences, it has now bottomed. In addition, in the fourth quarter, the team made further progress in bringing down lead times to our customers, which are now broadly at pre-pandemic levels. At the same time, some customers slowed ordering to better manage their year-end inventory levels and cash flows. This dynamic resulted in a book-to-bill of 0.7, which was in line with our expectations and should represent the bottom of our bookings trajectory with sequential improvements expected from here. Speaking to the business environment more broadly, as we head into 2024, we are feeling confident in the diversity and breadth of our business portfolio to weather a dynamic environment. As we mentioned in our last earnings call, we continue to see a somewhat weaker demand environment in the first half of 2024 in line with the growth rates we experienced in the second half of 2023. We expect the second half of 2024 to be characterized by a stabilizing interest rate environment with accelerating Novanta momentum on the back of new product launches. We are excited about and confident in the record demand of new product launches we're planning on in 2024. Going into more detail, for the full year of 2023, sales to medical markets made up approximately 54% of total Novanta sales and grew 13% versus the prior year, driven by strong double-digit minimally invasive surgery, surgical robotics, patient monitoring, in vitro diagnostics, and DNA sequencing applications. In the fourth quarter, sales to medical markets remained steady and roughly flat versus the prior year, again making up approximately 54% of total Novanta sales. During the quarter, we saw stable levels of shipments to many of our surgical OEM customers. We also saw some decline in our shipments to our life sciences customers, driven by the deferral of end-user orders due to a higher interest rate environment. Turning to advanced industrial markets, for the full year of 2023, sales to advanced industrial markets, excluding microelectronic applications, were up 1% year-over-year. As a reminder, Novanta plays in advanced industrial applications with mid to high single-digit long-term growth driven by secular trends such as Industry 4.0, robotics and automation, and precision manufacturing. Our advanced industrial sales in the fourth quarter were down 1% year-over-year and made approximately 38% of total Novanta sales. This sales decline was in line with our expectations due to the rapid rise in interest rates and continued weakness in China, as well as other geopolitical disruptions. While these trends are expected to continue in the first half of 2024, customers are using the slowdown to catch up on next-generation innovations. Finally, in our microelectronics markets, which represented just 7% of sales in the fourth quarter, the performance was roughly the same as we said in our last call. For the full year of 2023, the overall drop in the microelectronics market was a 700 basis point headwind on total Novanta sales growth, which was larger than we originally anticipated. To repeat from before, excluding microelectronics, Novanta revenue growth for the full year was up high single-digit year-over-year. As we look out into 2024 and 2025, we remain excited that the composition of this end-market exposure will shift to more secular growing and less cyclical applications such as next-generation lithography. This application is expected to see a strong tailwind the rest of this decade as a result of global demand for artificial intelligence, electrification, and high-performance computing. We also expect the momentum in this market to sequentially improve with improving fab utilization and normalizing inventory levels. Across all our end markets, we continue to stay focused on gaining competent share with intelligent subsystems into multiple high-growth application areas. We are confidently leaning in with a record demand of new product launches in 2024, up 50% versus 2023, with more scheduled for 2025, all of which will lead to $50 million of new revenue in 2025 with strong growth in the next several years following that. As a reminder, a new product pipeline is geared towards intelligent subsystems in strategic growth applications minimally invasive surgery, robotic surgery, next-generation lithography, precision manufacturing applications, and precision motion solutions for robotics and automation applications. Now, let me touch on some of Novanta's strategic growth metrics. For our design wins in the fourth quarter, we saw growth of strong double digits versus prior year. We saw excellent design win activity in multiple businesses, particularly with our advanced industrial customers, which bodes well for future growth in those end markets. Although our full-year design wins were still modestly down year-over-year, this was partially driven by the large minimally invasive surgery in 2022. Excluding those large platform wins from prior year, Novanta had double-digit design win growth in 2023. Our Vitality Index in the fourth quarter was still at about mid-teens percent of sales. This was in line with our expectations. We expect our Vitality Index to rebound to above 20% in late 2024, driven by our pipeline of new product launches. We remain very excited by our momentum in customer wins and our strongest new product lineup in a decade. Based on this, we reiterate with confidence Novanta's long-term growth framework of consistent mid to high-single-digit organic growth through the business cycles. Next, I'd like to give you a brief update on Novanta's acquisition activities. As already mentioned, we were very pleased to announce that we completed the acquisition of Motion Solutions in January. As a reminder, Motion Solutions offers customized and high-precision motion subsystems and components to market-leading OEMs centered on medical and life sciences applications. They are a market-leading business, and their team shares our passion for customers, innovation, and solving complex technical challenges. The integration of Motion Solutions is on schedule, and we are seeing a high level of engagement with their team. We are impressed with the strong and sticky customer relationships they have with their OEM customers who are leaders in precision medicine and medical markets. By combining Motion Solutions with Novanta, it creates the potential to develop new and unique intelligent subsystems using our combined technology offerings. These joint product development activities have already gotten started, and although we are very early on, our teams are already working seamlessly together both on the new solutions as well as cross-selling each other's technology to our complementary customer bases. We will be including Motion Solutions as part of the medical solutions segment for reporting purposes because of the close alignment with the customer base in this segment. The financial outlook for Motion Solutions looks promising in line with our expectations, and it will be factored into the 2024 guidance with Robert, which Robert will share later in this call. Even with the Motion Solutions transaction, acquisitions remain Novanta's top priority for capital allocation. We have a strong pipeline of potential targets. Our balance sheet is strong and can handle additional transactions, so you should expect us to continue to be active in the marketplace in 2024. Now, I'd like to share a few comments on how we continue to evolve our culture of Novanta called the Novanta Way. We believe that the Novanta Way has been a differentiator in attracting, retaining, and developing core talent. It's ultimately our talent and our culture that will make the difference. We continue to see below-market labor attrition rates both among our leadership ranks as well as across all our company employees. We're focusing on a few factors to retain our employees: competitive pay, a great company culture, and career development and progression. We continue to focus on improving our employee engagement scores, and we have invested heavily into leadership development initiatives and employee training on the Novanta Growth System. Sustainability also remains an important topic for Novanta. We've made steady progress on our long-term journey, reducing our environmental footprint. In a few weeks, we will be publishing our 2023 sustainability report, where we will share details on our goals and our accomplishments. One of the most critical aspects of our company culture is embedding the Novanta Growth System or NGS to drive excellence into the many ways we work together. In 2023, we've accelerated deployment of the Novanta Growth System deeper into the organization, completing a few dozen Kaizen events, launching many structured problem-solving actions, deploying rigorous daily management routines, using 80/20 portfolio management, and utilizing project management planning activities at all levels of the organization to fundamentally improve our operating results. We trained hundreds of Novanta employees on using the NGS tools, from leaders to frontline employees. These efforts have had a dramatic impact on our operations, including throughput and yield improvement in our factories, improving our supply chain and planning processes to enhance delivery performance to our customers, accelerating material and labor productivity, reducing cycle time of back-office processes, and improving time to market over new product launches. NGS is truly becoming a fundamental part of Novanta's identity, and it's helping unite our employees by giving us a common language and a common way of collaborating, which is increasing teamwork and successful problem-solving. We are very excited to continue to evolve NGS as we head into 2024. In summary, Novanta delivered solid operating performance in 2023 while navigating a dynamic macroeconomic environment. We achieved record sales, strong margin expansion delivered on our profit commitments, and improved cash flows. We've made great progress in deploying the Novanta Growth System and had continued success at further establishing a thriving company culture. We enhanced our portfolio with the Motion Solutions acquisition, which further expands our presence in highly attractive medical and precision medicine end markets. As we look to 2024, we have three priorities. First, launch and ramp a record set of new products. Second, expand our margins and cash flow using NGS. Third, continue to acquire additional companies that fit our strategy at attractive returns. With that, I will turn the call over to Robert to provide more details on our operations and financial performance. Robert. Thank you, Matthijs, and good morning, everybody. Our fourth-quarter non-GAAP adjusted gross profit was $100 million or 47% adjusted gross margin compared to $98 million or 45% of the adjusted gross margin in the fourth quarter of 2022. For the quarter, adjusted gross margins were up 220 basis points year-over-year. For the full year of 2023, non-GAAP adjusted gross profit was $413 million or a 47% adjusted gross margin compared to $392 million or a 46% gross margin in the prior year. 2023 adjusted gross margins were up 120 basis points year-over-year, which exceeded our goal. This represented a fantastic outcome for our teams, especially considering the slight drop in volumes in the second half of the year. Our success with gross margin expansion in the year was largely driven by the deployment and adoption of the Novanta Growth System productivity tools in our factories and in our operating teams. Moving on to operating expenses, for the fourth quarter, R&D expenses were roughly $23 million or approximately 11% of sales. For the full year, R&D expenses were roughly $92 million or approximately 10% of sales. Fourth-quarter SG&A expenses were slightly below $42 million or roughly 20% of sales. For the full year, SG&A expenses were $164 million or roughly 19% of sales. Adjusted EBITDA was approximately $45 million in the fourth quarter or a 21% adjusted EBITDA margin versus $46 million in the prior year. For the full year of 2023, adjusted EBITDA was approximately $196 million or a 22% adjusted EBITDA margin versus $184 million in the prior year. EBITDA margins expanded by roughly 100 basis points year-over-year. On the tax front, our non-GAAP tax rate for the fourth quarter was 21%. This differed from the statutory rate due to jurisdictional mix of income. For the full year of 2023, our non-GAAP tax rate was just above 16%, which was flat with the prior year. Our non-GAAP adjusted earnings per share was $0.63 in the fourth quarter compared to $0.75 in the fourth quarter of 2022. For the full year of 2023, our non-GAAP adjusted earnings per share was $3.02 compared to $3.07 in the full year of 2022. Our EPS performance in 2023 was obviously impacted by the significant increase in interest rates on our debt impacting interest expense. Fourth-quarter operating cash flow was approximately $39 million, or for the full year, operating cash flow was approximately $120 million compared to $91 million in the prior year, representing an increase of 32% year-over-year. We are pleased with the improvement in cash flows in the second half of the year, and we expect to carry this momentum into 2024 as we continue to rigorously manage our working capital and drive operating profits. We ended the year with gross debt of $358 million with a gross leverage ratio of approximately 1.8x. Our net debt was $253 million, positioning the company well to fund further acquisitions. Turning to backlog and bookings, we ended the year with a backlog of $473 million, which was still above pre-pandemic coverage levels but is closer to our expectation of backlog coverage on a go-forward basis. Our book-to-bill in the fourth quarter was 0.70, which was largely in line with our expectations. This low book-to-bill reflects both the continued reduction of lead times by our customers back to historical levels as well as some impact from customers reducing inventory levels to maximize their cash positions at year-end and to a lesser extent to deal with the lower visibility macroeconomic dynamics. I'll now turn to an update of the performance of the operating segments. First, I'll speak to the precision medicine and manufacturing segment. Fourth-quarter sales declined 5% year-over-year, which was slightly more than our prior guidance. The book-to-bill in this segment was 0.50 for the fourth quarter, driven by end-market demand deferrals in life science and advanced industrial applications and deferrals and purchases by our customers to maximize the year-end cash flows, which are the dynamics we previously just discussed. We have confidence these were temporary dynamics, as over the last two months, we've already experienced a sequential improvement in order activity. Therefore, we believe our order volume hit its bottom and expect it to rebound as we progress into the new year. Despite the weaker fourth quarter, for the full year of 2023, this segment demonstrated strong financial performance overall. The segment delivered 3% year-over-year revenue growth and adjusted gross margin expansion of over 200 basis points. The book-to-bill for the full year was 0.78, which mainly reflects the continued normalization of lead times as customers adjusted their backlog coverage closer to pre-pandemic levels as well as the previously discussed softening of demand from life science and advanced industrial markets. With precision medicine and manufacturing, new product revenue stayed strong at greater than 20% of sales in the fourth quarter, which is the same for the full year. Design wins in this segment were up strong double digits year-over-year in the fourth quarter, and the segment achieved design win growth for the full year based on the strength of the fourth quarter results. We're excited about the progress being made with multiple large strategic customers, which gives us the confidence we see growth in this segment returning later in the second half of 2024. Turning to the robotics and automation segment, this segment experienced a revenue decline of 10% year-over-year in the quarter. This was in line with our expectations and prior guidance. The decline was mainly driven by the impact of weaknesses in the sales to advanced industrial end markets, largely caused by industrial robotics dynamics and microelectronics weaknesses that we reported in the last quarter. The headwinds related to microelectronics have showed signs of stabilizing, and some green shoots of growth started to materialize, particularly in China. While these end-market dynamics are expected to repeat in the first quarter, we are starting to see signs of markets sequentially improving as we enter 2024. The overall book-to-bill ratio in this segment for the quarter was 0.93, which is a sequential improvement and is indicative of a more stable demand environment across the segment and its end markets. Our ATI business saw a book-to-bill greater than one in the fourth quarter, which further strengthens our confidence in a sequentially improving industrial robotic market in 2024. For the full year of 2023, robotics and automation segment saw sales decline 11% year-over-year, mainly driven by the headwind from sales to microelectronics. Book-to-bill for the full year was 0.83. Despite the challenges the segment faced, it still successfully expanded gross margins over 50 basis points for the full year, which was an impressive outcome. New product revenue was roughly 10% of sales for the segment in the quarter and for the full year. Design wins in this segment more than doubled year-over-year. In full year, design wins grew strong double digits. The design win strength further solidifies our confidence in 2024 and beyond. Finally, in medical solutions, this segment experienced reported revenue growth of 5% year-over-year, which was in line with our expectations. Growth in this segment continues to be driven by strength in elective surgical procedures as well as our JADAK business line, where the business continues to perform well thanks to broader strength in hospital spending. The medical solutions segment saw a book-to-bill of 0.70 in the fourth quarter. The weaker bookings mainly reflect the normalization of lead times and softening of demand from some life science end markets. However, we also saw some timing-related impacts from some of our medical customers managing the year-end inventory levels and from reducing orders on legacy product platforms as they ready their ramps for their 2024 new product launches in the second half. For the full year, this segment saw excellent growth, growing 17% year-over-year. The book-to-bill for the full year was 0.92. This reflects the resilient strength of demand in medical end markets. We are pleased to see this segment deliver strong adjusted gross margins with margins increasing 200 basis points for the full year. This is driven by the dedicated efforts of our operating teams who are having success at deploying the Novanta Growth System tools deeper into their business operations. The Vitality Index in this segment remained at mid-teens percent of sales level, in line with our expectations. As we mentioned before, we expect this metric to significantly rebound later in 2024 as we launch multiple new products with our customers in the second half of 2024. Overall, our segments performed as we expected in the quarter, and they were able to handle a variety of obstacles caused by a shifting macroeconomic environment. It's a testament to the strength of the talent in our businesses and the flexibility to adapt to a rapidly changing set of challenges. We are proud of our team's performance. Now, turning to guidance. In our medical end markets, we expect to see different dynamics between our exposure to surgical equipment versus life science and precision medicine equipment. For surgical equipment, we are expecting a strong year of growth. In the first half of the year, our legacy products will trend down, muting growth as both customers phase them out in anticipation of new product launches and as we proactively phase out less attractive products to create capacity for the new product launches in the second half. However, these new launches are expected to lead to low double-digit growth in the second half, allowing us to finish the year strong and positioning us well to sustain this growth into 2025 and beyond. For life science and precision medicine equipment, we expect continued temporary weakness in the first half due largely to the interest rate environment pressuring capital spending in this industry, which will result in low single-digit declines in sales. However, in the second half, these applications should return to growth as both product launches kick in and interest rates normalize, allowing the broader biopharma equipment market to stabilize and gradually improve. We expect these dynamics will lead to overall growth rising to low single-digit levels in the second half. In total, for the full year, we expect our medical markets to see growth, with strong growth weighted in the second half. In our advanced industrial end markets, we again see two different dynamics split between microelectronics versus all other applications. In microelectronics, which represent approximately 7% of sales now, we are seeing some early signs of improvement in the marketplace. We expect this end market to have flat growth in the first half of the year, but it's expected to return to low double-digit growth in the back half of the year. This is caused by both incremental improvements in the end market and the impact of new product launches, mainly in next-generation lithography. For the remainder of our advanced industrial exposures, these applications are more sensitive to the interest rate and macroeconomic dynamics and therefore expect to see low single-digit decline in the first half of the year. However, in the second half of the year, we expect to see gradual improvement in demand as interest rates normalize, new products and platforms ramp, and 2025 demand starts to appear in the order books, resulting in growth in the low to mid-single-digit range. In total, our advanced industrial markets should be roughly flat for the full year but showing solid growth in the fourth quarter. To start in the guidance for the full year of 2024, for revenue guidance, we now expect GAAP revenue in the range of $975 million-$1 billion. This would represent low single-digit organic growth for the full year. On the segment level, we expect precision medicine and manufacturing segment revenue to grow low single-digit percent on a year-over-year basis. Our robotics and automation segment revenues are expected to grow low single-digit percent year-over-year. And finally, our medical solutions segment, which now includes the Motion Solutions acquisition, we expect strong double-digit reported growth driven largely by the addition of Motion Solutions and low single-digit organic growth. Moving on to Novanta's adjusted gross margin, we expect gross margin for the full year to be approximately 46%-47%, which is roughly flat year-over-year. Novanta's core gross margins, excluding the Motion Solutions acquisitions, will be up 100 basis points from the prior year. As we mentioned before, the Motion Solutions business will be dilutive in the first year or two as we shift their business into higher gross margin products and solutions. In the segments, both the precision medicine and manufacturing segment and the robotics and automation segment should see healthy margin expansion for the full year in the range of 100-150 basis points as both these segments continue to execute on margin expansion plans using the Novanta Growth System tools. The medical solutions segment is expected to have gross margins down 50-100 basis points versus the prior year, where strong margin expansion in Novanta's core business is offset by the dilutive impact of Motion Solutions. Turning to R&D and SG&A expenses, they are expected to be approximately $280 million-$290 million for the full year. The increase in cost year-over-year is largely driven by the addition of Motion Solutions as well as labor cost increases and further investments in our innovative pipeline and some further investments in our commercial engine. Depreciation expense should be approximately $16 million for the full year, and stock compensation expense should be approximately $29 million for the full year. For adjusted EBITDA for the full year of 2024, we expect a range of $215 million-$225 million. Interest expense, which was nearly $26 million in the full year of 2023, is expected to be roughly $31 million for the full year of 2024. The higher interest rate expense year-over-year is driven by the additional borrowing on the Motion Solutions transaction. We expect our non-GAAP tax rate to be around 18% for the full year of 2024. The guidance includes our current view of the impact of OECD Pillar Two global minimum tax rates. Our current view is that Novanta has some exposure here, which has been factored in, but the United States and China have not yet enacted the rules yet. Due to the uncertainty of whether and which countries will enact the rules, the timing of individual country legislation actions, and the underlying complexity of the rules, the impact on us is not reasonably estimatable at this time. Diluted weighted average shares outstanding will be approximately 36 million shares. For the full year of 2024, adjusted earnings per share is now expected to be $3.10-$3.35. For the first quarter of 2024, revenue guidance, we expect GAAP revenue in the range of $225 million-$230 million, which represent organic revenue declines between 6% and 4% on a year-over-year basis. We believe the first quarter represents the bottom for Novanta's revenue on an organic basis due to both end market demand weaknesses and legacy products phasing out in advance of new product launches in the second half. On a segment level in the first quarter, we expect precision medicine and manufacturing revenue to decline mid-single digit on a year-over-year basis. Our robotics and automation segment revenue is expected to decline low double-digit percent, and our medical solutions segment is expected to demonstrate year-over-year double-digit reported revenue growth in the first quarter, driven largely by the addition of Motion Solutions. Organically, we expect this segment to be roughly flat year-over-year. Moving on to adjusted gross margin, we expect to be approximately 45.5%-46% in the first quarter, which is roughly flat year-over-year. In the segments, gross margins are expected to be flat to up sequentially in precision medicine and manufacturing and robotics and automation. The medical solutions segment is expected to have a sequential decline in gross margins in the first quarter due to the dilutive impact of Motion Solutions. For R&D and SG&A expenses, we expect to be approximately $69 million-$70 million. Depreciation expense will be approximately $4 million in the first quarter. Stock compensation expense will be approximately $8 million. For adjusted EBITDA, we expect to range of $45 million-$48 million. Interest expense is expected to be roughly $9 million, and we expect our non-GAAP tax rate to be around 18%. For adjusted diluted earnings per share, we expect a range of $0.55-$0.60. Following the close of the Motion Solutions acquisition, we expect gross debt at the end of the first quarter to be roughly $500 million, giving us a gross leverage ratio of approximately 2.5x. From a net debt perspective, we expect to be around 2x. Presuming no further acquisitions, our gross debt is expected to return to year-end 2023 levels by year-end 2024. Finally, we expect cash flows to continue to improve in 2024 following the momentum of the second half of 2023 as we continue to rigorously manage our inventory and overall working capital levels. We expect first quarter cash flow to be somewhat lower than the remainder of the year due to the timing of incentive compensation payments, equity compensation vesting events, timing of seasonal tax payments, and the timing of certain capital expenditures related to the completion of our Manchester, U.K. facility. However, we expect cash flow to strengthen as the year progressing, putting us in a great position to accelerate our acquisition strategy. As always, this guidance does not assume significant changes to foreign exchange rates. To wrap up guidance, we are excited about the prospect of delivering $1 billion in sales in 2024. We continue to feel strongly that we are in the right end markets with attractive exposure to secular growth applications and the right strategy for long-term growth. In summary, Novanta's performance in the fourth quarter and full year 2023 was solid and reflected excellent execution by our teams. Our teams delivered revenue and profit performance above our expectations in a dynamic operating environment. This performance is yet another testament to the diversification and resiliency of our business portfolio and the tenacity of our teams to achieve great results no matter the business environment. Looking towards 2024, we are confident in our ability to navigate the short-term market-based challenges and deliver on an ambitious plan for the year, including on executing new product launches happening in the second half of the year. We continue to see long-term growth prospects remaining strong and even accelerating on the back of exciting new product launches and our exposure to high-growth end markets to both medical and advanced industrial applications. We look forward growing Novanta to a $1 billion company and beyond, and we feel we have the right playbook to continue to deliver predictable, consistent long-term growth and a shareholder value. We remain very confident in our outstanding performance of our employees and their efforts to help us be successful in a dynamic environment, and we remain grateful to our customers' confidence and faith in our ability to deliver to them the innovations they need to be successful. We look forward to continuing to deliver on our commitments to our employees, our customers, and our shareholders. This concludes the prepared remarks. We'll now open the call up for questions. We will now begin the question -and -answer session. To ask a question, you may press star then one on your touch-tone phone. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star then two. Our first question will come from Lee Jagoda of CJS Securities. Please go ahead. Hi. Good morning. Morning, Lee. Starting with the first half guidance, Robert, can you parse out how much of that guidance relates to the general macro in microelectronics and advanced industrial versus the piece where customers are basically pausing in anticipation of the new products later in the year? Yeah. I would say less pausing, more phasing out legacy products. So effectively, ramp down any product that's going to be replaced with a new product to ensure you have a more successful launch on the new product launches. So I would say for overall Novanta, roughly half of it is related to that, and half of it is the macroeconomic environment. Gotcha. And then looking at your full-year revenue guidance, obviously second half weighted, can you talk to the range of that guidance and how much of the lower high end of that range is based on the macro getting better, and how much is based on the timing of the product launches at your customers? Yeah. So we're not relying on, I would say, an improving macroeconomic environment to get to $1 billion. The $1 billion represents the things that we can control. So obviously, there's more stabilization in the market, and you'll see sequentially improving environment. But we're not betting on a very large improvement in the macroeconomic environment in the second half in order to hit the top end of the range. The bottom end of the range represents a deterioration of the macroeconomic environment. So the way we see it today is we're sort of trending towards that $1 billion. If things worsen for geopolitical reasons or some other shoe drops on a macroeconomic perspective, then that's where we see ourselves trending to the lower end of the range. There's nothing that we see today that would necessarily deliver that, but we wanted to be prudent in the guidance for the full year. That's fair enough. One more, and I'll hop back in queue. Obviously, the world of medicine is driving a lot of the growth coming in late 2024 and into 2025. Can you talk to some of your customers' product roadmaps as you look out to 2025 and maybe speak to any other significant products or specific drivers of growth beyond the world of medicine that we should start to think about? Yeah, Lee. This is Matthijs. Yeah. So I spoke about that the amount of products that we're launching this year is 50% larger than last year. And so that's a record amount of new product launches, and they're pretty broad-based. So it's not all world of medicine, right? So we've spoken a lot about, I think, the smoke evacuation side, of course, that we think is going to be a standard of care for the next decade, as well as the pump side of that business that we're getting into, and we're getting successful design wins. But beyond that, I've talked before, but let me repeat that we're gaining content in the DUV/EUV lithography side of the business that is an exciting application for us. We expect that to show some first revenue later in the year and then strong momentum in 2025. We see a lot of intelligent subsystem momentum in precision medicine and spatial biology and multiomics on the back of our MOSO or Motion Solutions acquisition. What we're seeing is Motion Solutions has a lot of a great customer base in the segments that we were eyeing, and they already know the people there. So we can accelerate our strategy there that way and vice versa. We can help Motion Solutions to accelerate in customers that we are in and they're not. Then we see beam delivery subsystems for advanced micromachining, electric vehicle battery welding, converting. We've spoken about this as well in the past, and these products are launching as we speak or are being launched in the second half of the year in 2025. I mean, you see an overall trend of more precision, more accuracy at super high throughput. And yeah, we have leading technology there. So whenever you see applications that will drive next-generation manufacturing technologies to achieve these accuracies, like 3D printing, like electric vehicle battery welding, like, let's say, precise medical manufacturing, right, at sub-micron level, chances are we're in those machines. And there's a trend more towards intelligent subsystems that we're excited about. And then we got the whole robotics and automation space, of course, on the back of our ATI acquisition, but also on the back of our own, let's say, original core business where we see both the sensing, the force-torque sensing, as well as the positioning and the intelligence that drives all gaining momentum in robotic surgery, but also warehouse automation and general industrial robotics markets, right? So it's basically we are enabling a sense of touch and motion control in these applications with unique, yeah, proprietary technology. So in other words, the list is long. The impact is a bit more consolidated in the OEM business, for sure, but you see a large breadth of new products and applications. Therefore, that's why we feel confident and are excited about that breadth and that potential. That's great color. Thanks very much. I'll hop back in queue. Sure. The next question comes from Brian Drab of William Blair. Please go ahead. Hi. Good morning. Thanks for taking my questions. Robert, you ran through a lot of numbers really quickly in terms of the guidance. So sorry if I missed this, but can you aggregate all the dynamics that are occurring in the second half and tell us what you expect for overall company revenue growth in the second half? I think if you do the range, if you base it off of what I gave in guidance for the first quarter and then look at the full year—let's say you're trending up towards like $1 billion for the full year—you'll probably see growth return to our long-term growth averages in the third quarter, and then in the fourth quarter, getting to double-digit type growth as the new products really kick in in a number of different areas, including in the medical solutions being the magnitude of that. What that would somewhat signal is the first half of the year being down organically, with it being down more in the first quarter and really less in the second quarter. So that's the dynamics. And I would say that the first half performance is more complicated than the second half. The second half performance is really just a stabilization of the market driven by new product introductions driving growth above, let's say, macroeconomic conditions. In the first half of the year, you have some customers pulling back on any sort of legacy products to make their launches more successful in the back half of the year. And so you've got inherent weakness in the life science space, continued weakness in the industrial space, strength on the medical side being somewhat offset by the fact that they are scaling or phasing out those legacy products. But the overall year, we feel pretty good about. So as I said before to the last color, we're trending right now closer to that $1 billion level based upon the economic conditions. We're not banking on the economic conditions improving in order to get there. We're really just assuming that the current stabilized market environment that we're operating in will continue on, and our new products will accelerate our growth in the second half. Great. And you made this comment, I think, pertaining to one specific segment, but you said that if we can get to low double-digit growth in the second half, expect to be able to sustain that as you enter 2025. I think that was for one segment. That wasn't for the company overall, or does that kind of comment probably pertain to the company overall as well? Yeah. I think it gives us the greatest. Most of that was related to the medical solutions area because you have a larger above-average ramp in new products. Effectively, we've talked about this before. Within the MIS space, we have won a multitude of new customers for our next generation, second generation smoke evacuation products. And so that resulted in that double-digit growth in the fourth quarter, and then that continued momentum goes into 2025 because of those new product launches. That's a dynamic that Matthijs talked about around that $50 million of incremental new product revenue being driven from that. There's an element of that also benefiting our precision medicine and manufacturing segment. So there should be a little bit stronger growth in 2025 as well. I didn't want to kind of get into that as much. There's some other dynamics in play that are a little bit more complicated to forecast at this point. But clearly, ramping up in next-generation lithography and the continued strength and recovery that we expect from next-generation DNA sequencing will help that segment drive strong growth as we exit 2024. Okay. And my last question for now, I'm going to push this line of questioning just a little bit further. But how important is the consumables revenue stream that's going to follow or should follow the introduction of the new insufflator, some of these platform wins? Consumables has been a relatively small part of the business, but does that get bigger following these intros? Yeah, it absolutely does. So I don't want to get into how big it is because that would be the question you asked next. But it effectively will double as well. And so the medical consumables, the great attractiveness around that is that it's a consumable. It's not tied to capital cycles. It will be very tied to surgical procedure rates. Surgical procedure rates are around 6% on a global basis. And so you drive this very steady annuity of around 6% in the medical field tied to our proprietary second-generation smoke evacuators, and it allows us to drive real sustainable cash flow streams. Now, even though we've talked about it before, we've ramped and completed our Czech Republic manufacturing facility. We are pushing volume through that now. It is complete and qualified and so confident that we will begin to insource that. That will drive the higher gross margin expansion in that segment for the next few years. It also allows us to really drive a higher EBITDA margin because the medical consumables don't have the operating expenses. They leverage off of the capital equipment sales. And then think of them as being. It's recurring. As soon as we get the system in place, we have that annuity stream lasting up to 10 years off of those systems, Matthijs. Yeah. No, that's great, color, Robert. I would just say underneath, right, Brian, it's about winning capital equipment slots, right? So you can kind of drive the installed base or rather the customers can drive. So we've won new slots that we never had before. And then we've won slots where we didn't have priority consumable revenue streams. In other words, the percentage of business where we've won basically touch rates with consumables has increased with those design wins. Secondly, there's a trend towards more, I would say, sophisticated consumables, which means higher ASPs, right? We're solving more and more complex problems to make sure that more and more, I would say, indications can be served with our consumables. Yeah. And then third, we're entering into pumps, which in a way is kind of a greenfield opportunity for us where we didn't have a position to begin with. So all these things together, you can kind of see where we win more installed base. That will drive more consumables. We have higher ASPs, and that will then drive, of course, additional growth. And over time, I think in this business, you can expect that consumable business to be larger, yeah, than our capital equipment business. Perfect. Okay. Thanks very much. Thank you. The next question comes from Rob Mason of Baird. Please go ahead. Hi. Good morning. I wanted to circle back to just try to get clarification. Robert, within your full revenue guidance for the year, low single-digit core growth, you said, so I'm assuming around $85 million-$90 million from Motion Solutions. What is the headwind from some of the product rampdown that's dialed into that low single-digit core growth, right? Yeah. I won't give an exact number, but if you take the first half growth rates, I would say half of it is related to, half of the decline is related to the macroeconomic environment, and half of the decline is related to the product rampdowns of legacy products and just management of those legacy products by our customers. So if you take that in the full year, organic, kind of that low single -digit, you'd probably be closer to something in the mid-single digit territory for the full year. So that gives you a little bit of that scaling, right? And it's mostly a first-half dynamic versus second-half dynamic, which is where it's kind of predominantly related to the medical solutions side of the segments. Okay. And appreciate the commentary just around medical overall high level between the surgical exposure versus life sciences patient monitoring. How does that exposure break down? Or what percent is surgical versus life science patient monitoring? I think it's a question that we are delinquent on answering. You've asked us that a few times. We do have to get some information out on that. I apologize for not completing that by year-end. It's fair to say overall kind of medical solutions is roughly half of it is tied to more of a pure minimally invasive surgical business, and then the other half of it tied to more of that mix of life science, precision medicine, and some stuff going into patient monitoring equipment and drug dispensing equipment. So it's roughly 50/50 in the medical solutions segment overall. Okay. Okay. And just maybe last question. Matthijs, you had noted ATI seeing some improvement in their bookings in the robotics space. Could you just maybe isolate on where they were seeing some of those improvements? Is China part of that improvement, or what's the perspective how China factors into advanced industrial in the outlook as well? Yeah. I mean, China, we're seeing some modest improvement, but I think it's fair to say we're not banking on an improvement there for the full year, right? Because, yeah, I would say that's probably the region where we have least visibility and where it's, yeah, toughest to say when that will turn. Now, having said that, we do feel that globally, and particularly in the U.S., inventories have worked their way down or are working their way down. And therefore, we think towards, yeah, sequentially, basically, in the year, that will improve and drive the momentum. So I would say regionally, probably U.S. the strongest, Europe bottoming, and then China remains to be seen, although we see some green shoots there as well, albeit from a low level. Yeah. And we're not in our guide assuming a massive recovery or so. Yeah. Okay. Very good. Thank you. Thanks, Rob. This concludes our question and answer session. I would like to turn the conference back over to Mr. Matthijs Glastra for any closing remarks. Thank you, operator. So to recap, Novanta delivered solid performance in 2023 in the fourth quarter and for the full year. Our teams delivered revenue and profit performance above our expectations in a dynamic operating environment. We achieved record revenue, excellent gross margin expansion, and solid profit and cash flow performance. This came despite some challenging headwinds in the end markets we serve. We secured the Motion Solutions acquisition, which will be an attractive growth platform for us in 2024 and beyond. So Novanta remains well-positioned in the medical and advanced industrial end markets with diversified exposure to long-term secular macro trends in robotics and minimally invasive surgery, and Industry 4.0. In 2024, we're excited for the large product launches starting later this year. We will continue to focus on additional design wins and high-growth applications, as well as doubling down on the Novanta Growth System to drive strong cash flows and gross margin expansion. In closing, as always, I would like to thank our customers, our employees, and our shareholders for their ongoing support. I continue to be especially grateful for all the dedicated efforts of all our employees who work so diligently every day and taking on new challenges and striving to make the company a great place to work. We appreciate your interest in the company and your participation in today's call. I look forward to joining all of you in several months in our first quarter and 2024 earnings call. Thank you very much. This call is now adjourned. The conference has now concluded. Thank you for attending today's presentation, and you may now disconnect.